
Much effort has been expended to develop inhibitors against protein-tyrosine phosphatases (PTPs), nearly all of it unsuccessful. A recent report, describing a highly specific, orally bioavailable inhibitor of the PTP oncoprotein SHP2 with in vivo activity, suggests that allostery might provide a way forward for PTP inhibitor development.
Mice, Neoplasms, Animals, Humans, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Molecular Targeted Therapy, Protein Kinase Inhibitors
Mice, Neoplasms, Animals, Humans, Protein Tyrosine Phosphatase, Non-Receptor Type 11, Molecular Targeted Therapy, Protein Kinase Inhibitors
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 91 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
